EZH2, a histone methyltransferase, is overexpressed in several human tumors, but whether it exerts any impact in chronic lymphocytic leukemia (CLL) remains unknown. We used real time PCR to investigate the expression profile of EZH1 and EZH2 in 59 CLL patients, 10 samples of purified B-cells from healthy donors and 12 normal adult tissues. EZH2 was overexpressed in CLL patients and correlates with high white blood cell count, ZAP-70 expression and chromosomal abnormalities. EHZ1 expression does not correlate with CLL progression. EZH2 overexpression is related to a poor prognosis of CLL and could be a useful tool to assess its aggressiveness
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...
EZH2 genetic mutations are common in myelodysplastic syndrome (MDS), which implies that this gene ha...
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...
Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesi...
Enhancer of zeste homolog 2 (EZH2), an epigenetic regulator and H3k27-specific histone methyltransfe...
Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during c...
Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is char...
Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy fo...
International audienceThe histone methyltransferase EZH2 has an essential role in the development of...
In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high mortality amo...
T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10-15 % of pediatric ALL cases. EZH2, one...
Abstract Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a catalytic component o...
Epigenetic regulators are commonly mutated in cancer. Activating mutations and overexpression of EZH...
Myelodysplastic syndrome (MDS) is characterized by clonal hematopoiesis and impaired differentiation...
T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available ...
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...
EZH2 genetic mutations are common in myelodysplastic syndrome (MDS), which implies that this gene ha...
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...
Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesi...
Enhancer of zeste homolog 2 (EZH2), an epigenetic regulator and H3k27-specific histone methyltransfe...
Background: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during c...
Lymph node involvement of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) is char...
Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy fo...
International audienceThe histone methyltransferase EZH2 has an essential role in the development of...
In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high mortality amo...
T-cell Acute Lymphoblastic Leukemia (ALL) represents about 10-15 % of pediatric ALL cases. EZH2, one...
Abstract Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a catalytic component o...
Epigenetic regulators are commonly mutated in cancer. Activating mutations and overexpression of EZH...
Myelodysplastic syndrome (MDS) is characterized by clonal hematopoiesis and impaired differentiation...
T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available ...
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...
EZH2 genetic mutations are common in myelodysplastic syndrome (MDS), which implies that this gene ha...
Alterations to the gene encoding the EZH2 (KMT6A) methyltransferase, including both gain-of-function...